OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 1030
- Registration Number
- NCT05593029
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 19
- Registration Number
- NCT05542264
- Locations
- 🇺🇸
Shari DeSilva, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-03-27
- Target Recruit Count
- 336
- Registration Number
- NCT05536414
- Locations
- 🇺🇸
Yuma CNS Research, Yuma, Arizona, United States
🇺🇸SanRo Clinical Research Group LLC, Bryant, Arkansas, United States
🇺🇸Sunwise Clinical Research, LLC - Lafayette - IVY - PPDS, Lafayette, California, United States
Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 15
- Registration Number
- NCT05463770
- Locations
- 🇺🇸
CNRI - San Diego LLC, San Diego, California, United States
🇺🇸Catalina Research Institute LLC, Montclair, California, United States
🇺🇸Pillar Clinical Research, LLC, Richardson, Texas, United States
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- Other: placebo capsule
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 574
- Registration Number
- NCT05428033
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard
- Conditions
- Schizophrenia
- Interventions
- Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-06-26
- Target Recruit Count
- 31
- Registration Number
- NCT05402111
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Research, LLC, Long Beach, California, United States
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit/Hyperactivity Disorder
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2025-04-15
- Target Recruit Count
- 680
- Registration Number
- NCT05279313
- Locations
- 🇺🇸
CenExcel-iResearch, LLC, Decatur, Georgia, United States
🇺🇸Neurobehavioral Medicine Group, Bloomfield, Michigan, United States
🇺🇸Precise Research Centers, Flowood, Mississippi, United States
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-09-27
- Target Recruit Count
- 459
- Registration Number
- NCT05257265
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States
Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Drug: Sibeprenlimab 400 mg s.c. Q4weeks
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 600
- Registration Number
- NCT05248659
- Locations
- 🇺🇸
For additional information regarding sites, contact 844-687-8522, New York, New York, United States